Evidence map›Paper›PMID 40073160›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2025

MyD88 determines T cell fate through BCAP-PI3K signaling.

Abraham L Bayer, Zoie Magri, Hayley Muendlein, Alexander Poltorak, Pilar Alcaide

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abraham L BayerDepartment of Immunology, Tufts University School of Medicine, Boston, MA, United States.ORCID 0000-0001-7534-6354
Zoie MagriDepartment of Immunology, Tufts University School of Medicine, Boston, MA, United States.ORCID 0000-0001-9378-4278
Hayley MuendleinDepartment of Immunology, Tufts University School of Medicine, Boston, MA, United States.
Alexander PoltorakDepartment of Immunology, Tufts University School of Medicine, Boston, MA, United States.
Pilar AlcaideDepartment of Immunology, Tufts University School of Medicine, Boston, MA, United States.ORCID 0000-0003-3013-3982

Funding

Hyper-Responsiveness to TLR Agonists in Wild Derived MiceR01AI056234 · NIAID · TUFTS UNIVERSITY BOSTON · PI POLTORAK, ALEXANDER · 2003 to 2023
$8.4M
Regulation of LPS-responses by ZBP1R01AI167245 · NIAID · TUFTS UNIVERSITY BOSTON · PI POLTORAK, ALEXANDER · 2021 to 2025
$3.6M
Mechanisms of T cell activation in cardiac fibrosis and non-ischemic heart failureR01HL144477 · NHLBI · TUFTS UNIVERSITY BOSTON · PI ALCAIDE ALONSO, MARIA PILAR · 2019 to 2023
$3.2M
Regulation of T cell immune response in Heart Failure with Preserved Ejection FractionR01HL165725 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Maria Pilar Alcaide Alonso · 2023 to 2026
$2.5M
Spectral Cell SorterS10OD032201 · OD · TUFTS UNIVERSITY BOSTON · PI TAI, ALBERT K · 2022 to 2022
$672k
Comparing the role of MyD88 and TRIF in T-cell effector function and the development of heart failureF30HL162200 · NHLBI · TUFTS UNIVERSITY BOSTON · PI Abraham Bayer · 2022 to 2026
$238k
NHLBI NIH HHS F30 HL162200NHLBI NIH HHS R01 HL144477NHLBI NIH HHS R01 HL165725NIAID NIH HHS R01 AI056234NIAID NIH HHS R01 AI167245NIH HHS AI167245NIH HHS F30NIH HHS HL162200NIH HHS HL165725NIH HHS NIH R01 AI056234NIH HHS R01 AI056234NIH HHS R01 HL144477NIH HHS S10 OD032201NIH HHS S10OD032201
6 · The paper itself

Abstract

The life cycle of effector T cells is determined by signals downstream of the T cell receptor (TCR) that induce activation and proinflammatory activity, or death as part of the process to resolve inflammation. We recently reported that T cell myeloid differentiation primary response 88 (MyD88) tunes down TCR activation and limits T cell survival in the cardiac and tumor inflammatory environments, in contrast to its proinflammatory role in myeloid cells upon toll-like receptor (TLR) recognition of pathogen- and damage-associated molecular patterns. However, the molecular mechanism remains unknown. Here, we report a central regulatory role for MyD88 in T cell apoptosis after TCR activation and Fas ligation through an association with the B cell adaptor for phosphoinositide 3-kinase (B cell activating protein [BCAP]). We show that TCR engagement upregulates MyD88 and BCAP and promotes their interaction, thereby limiting availability of BCAP for downstream TCR-BCAP-PI3K-AKT signaling required for T cell activation and survival, which are enhanced in MyD88-/- activated T cells. Further, MyD88 and BCAP association and localization to the TCR was prevented by lipopolysaccharide (LPS) activation of TLR4 and restored T cell survival in wild-type cells. The enhanced T cell activation markers, proinflammatory signals, and survival advantage observed in MyD88-/- T cells was fully eliminatedef upon BCAP knockdown in T cells. Our data demonstrate that MyD88 acts downstream of the TCR to regulate T cell fate through its association with BCAP and elucidate a novel molecular mechanism for MyD88 in T cell biology that could be targeted to fine-tune T cell effector function and survival therapeutically.

Indexed as

Myeloid Differentiation Factor 88Phosphatidylinositol 3-KinasesSignal TransductionT-LymphocytesAdaptor Proteins, Signal TransducingAnimalsApoptosisCell DifferentiationCell SurvivalLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutProto-Oncogene Proteins c-aktReceptors, Antigen, T-CellAdaptor Proteins, Signal TransducingMyd88 protein, mouseMyeloid Differentiation Factor 88Phosphatidylinositol 3-KinasesPik3ap1 protein, mouseProto-Oncogene Proteins c-aktReceptors, Antigen, T-Cellapoptosiscell activationsignal transductionT cell receptorsT cells

Identifiers

PMID40073160
PMCPMC11952871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.